Skip to main content

Advertisement

Table 1 Description of the retrieved trials

From: Using Bayesian statistics to estimate the likelihood a new trial will demonstrate the efficacy of a new treatment

First author e-date Imaging Female/malea Age (mean) BMI (mean) RSG AC BOPH BOA IOD SR OB
Chareancholvanich 02/03/2013 mri 70/10 70 28 low uk high low low low uk
Victor 26/04/2013 mri/ct 86/42 67 - uk low high low high low high
Roh 03/08/2013 ct 82/8 70 27 low low high uk high low uk
Hamilton 06/08/2013 ct 31/21 68 31 uk uk high low high low uk
Boonen 10/08/2013 mri 106/74 67 30 low low high low low low low
Parratte 15/08/2013 mri 24/16 71 29 high low high low low low uk
Chotanaphuti 04/09/2013 ct 70/10 70 25 uk uk high low low low low
Woolson 07/03/2014 ct 0/63 66 33 low low high low high low low
Kotela 28/06/2014 ct 66/29 67 30 uk uk high low low low low
Pfitzner 16/07/2014 mri/ct 51/39 65b 30 low low high low low low low
Yan 14/09/2014 mri 41/19 69 - low uk high low low low uk
Abane 09/01/2015 mri 88/52 69 29 low uk high low high low low
Molicnik 04/03/2015 mri 31/7 67 33 uk uk high uk uk low uk
  1. RSG random sequence generation, AC allocation concealment, BOPH blinding of participants/care providers, BOA blinding of outcome assessors, IOD incomplete outcome data, SR selective reporting, OB other biases. a sex ratio in shown for patients randomized and outcome is shown for patients analyzed, therefore numbers may differ. b mean of group’s median